Determination of the GI and II Values of Soft Drink and Soft Drink With Sugardown™

NCT ID: NCT03374501

Last Updated: 2017-12-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was a partly controlled laboratory-based study comparing the glycemic and insulinemic indices of 3 test meals containing soft drink alone or with SUGARDOWN™ (Galactomannan) in overweight adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

STUDY SUMMARY This study was a partly controlled, laboratory-based study comparing the short-term postprandial glucose and insulin responses produced by three test meals containing soft drink consumed alone or with SUGARDOWN™, relative to the responses produced by an equal-carbohydrate portion of glucose solution (the reference food). The study used a repeated measures design, such that every subject consumed the reference food and each test food on two separate occasions, completing a total of eight separate test sessions. Each subject completed their test sessions on separate weekday mornings at a similar time each day, as close as possible to the time they would normally eat breakfast.

SUBJECTS Ten healthy, non-smoking, overweight or obese subjects (6 females and 4 males) voluntarily participated in this study. The mean ± SD age of the subjects was 32.4 ± 10.9 yr (range: 18.7 - 55.6 yr), and their mean ± body mass index value was 27.4 ± 2.6 kg/m2 (range: 25.3 - 32.3 kg/m2).

Volunteers were given detailed written and verbal information about all of the study's inclusion criteria and experimental procedures. If the volunteers decided that they would like to participate in the study, they were asked to come to the research centre on another morning, where they completed a detailed screening questionnaire that assessed their current health status and medical history. In order to participate in the study, the volunteers had to meet the inclusion criteria. All suitable volunteers that were invited to participate in the study were required to sign a detailed subject information sheet and a consent form before commencing any experimental procedures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postprandial Hyperglycemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Sugardown™ Galactomannan Postprandial blood glucose Insulin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2 tablets Sugardown™

Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 2 tablets of Sugardown™

Group Type EXPERIMENTAL

Sugardown™

Intervention Type DIETARY_SUPPLEMENT

Test food #2: 495.0 g Sprite™ soft drink plus 2 Sugardown™ tablet consumed with 250 mL water (repeated twice) Test food #3: 495.0 g Sprite™ soft drink plus 4 Sugardown™ tablet consumed with 250 mL water (repeated twice)

4 tablets Sugardown™

Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 4 tablets of Sugardown™

Group Type EXPERIMENTAL

Sugardown™

Intervention Type DIETARY_SUPPLEMENT

Test food #2: 495.0 g Sprite™ soft drink plus 2 Sugardown™ tablet consumed with 250 mL water (repeated twice) Test food #3: 495.0 g Sprite™ soft drink plus 4 Sugardown™ tablet consumed with 250 mL water (repeated twice)

Soft drink

Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink

Group Type PLACEBO_COMPARATOR

Soft drink

Intervention Type DIETARY_SUPPLEMENT

Test food #1: 495.0 g Sprite™ soft drink consumed with 250 mL water (repeated twice)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sugardown™

Test food #2: 495.0 g Sprite™ soft drink plus 2 Sugardown™ tablet consumed with 250 mL water (repeated twice) Test food #3: 495.0 g Sprite™ soft drink plus 4 Sugardown™ tablet consumed with 250 mL water (repeated twice)

Intervention Type DIETARY_SUPPLEMENT

Soft drink

Test food #1: 495.0 g Sprite™ soft drink consumed with 250 mL water (repeated twice)

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BTI320 PAZ320 Sprite™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 18-65 years.
* Non-smoker.
* Stable body weight within the overweight weight range for their height (BMI values 25 kg/m2 for Causcasian individuals and \>23 kg/m2 for Asian individuals).
* Normal dietary habits; not dieting or eating in an overly restrictive fashion in the past 3 months.
* A regular pattern of low to moderate physical activity.
* Able to fast for ≥ 10 hours the night before each test session.
* Able to refrain from eating a legume-based evening meal or drinking alcohol the day before each test session.
* Finds the test foods suitable for consumption within 12 minutes.
* Not taking any treatment for anorexia, weight loss, or any form of treatment or medication likely to interfere with metabolism or dietary habits.
* Signed the informed consent form for the study.

Exclusion Criteria

* Currently following a restrictive diet (low-calorie, low-carbohydrate, vegan).
* Any clinically significant physical or mental illness.
* Suffering from a food allergy or serious food intolerance.
* Regularly taking prescription medication other than standard contraceptive medication.
* Females who are currently pregnant, breast-feeding, trying to become pregnant or not using an acceptable contraceptive.
* Participating in another clinical trial or participated in another clinical trial within the two weeks.
* Undergoing general anaesthesia in the month prior to inclusion.
* Subject in a situation, which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jennie Brand-Miller

Role: PRINCIPAL_INVESTIGATOR

School of Molecular Bioscience, University of Syndey, Australia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PAZ320-004

Identifier Type: -

Identifier Source: org_study_id